Elevated Homocysteine by Levodopa Is Detrimental to Neurogenesis in Parkinsonian Model

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Shin, Jin Young ^a   Ahn, Young Hwan ^b   Paik, Man Jeong ^c   Park, Hyun Jung ^a   Sohn, Young H ^a   Lee, Phil Hyu ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Ajou University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; HOMOCYSTEINE; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PRAMIPEXOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL DEATH; COCULTURE; COMPARATIVE STUDY; CULTURE MEDIUM; DRUG ACTIVITY; IMMUNOCHEMISTRY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROGENIC ACTIVITY; NONHUMAN; PARKINSON DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DOPAMINE AGONISTS; FLOW CYTOMETRY; HOMOCYSTEINE; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; NEUROGENESIS; PARKINSON DISEASE; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ANIMALIA; PARKINSONIA;

EID: 84870340952     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050496     Document Type: Article

References (46)

1. Geraerts M, Krylyshkina O, Debyser Z, Baekelandt V, (2007) Concise review: therapeutic strategies for Parkinson disease based on the modulation of adult neurogenesis. Stem Cells 25: 263-270.
2. Abdipranoto A, Wu S, Stayte S, Vissel B, (2008) The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development. CNS Neurol Disord Drug Targets 7: 187-210.
3. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, et al. (2004) Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7: 726-735.
4. Crews L, Mizuno H, Desplats P, Rockenstein E, Adame A, et al. (2008) Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J Neurosci 28: 4250-4260.
5. O'Keeffe GC, Barker RA, Caldwell MA, (2009) Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain. Cell Cycle 8: 2888-2894.
6. Van Kampen JM, Eckman CB, (2006) Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 26: 7272-7280.
7. Postuma RB, Lang AE, (2004) Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 63: 886-91.
8. Diaz-Arrastia R, (2000) Homocysteine and neurologic disease. Arch Neurol 57: 1422-1427.
9. Muller T, Renger K, Kuhn W, (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61: 657-660.
10. Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, et al. (2003) Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 207: 19-23.
11. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R, (2003) Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60: 59-64.
12. Yong SW, Lee KY, Lee PH, (2010) The effect of levodopa treatment on cerebral hemodynamics in patients with Parkinson's disease: serial transcranial Doppler studies. Parkinsonism Relat Disord 16: 225-227.
13. Jara-Prado A, Ortega-Vazquez A, Martinez-Ruano L, Rios C, Santamaria A, et al. (2003) Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition. Neurotox Res 5: 237-243.
14. Poddar R, Paul S, (2009) Homocysteine-NMDA receptor-mediated activation of extracellular signal-regulated kinase leads to neuronal cell death. J Neurochem 110: 1095-1106.
15. Rabaneda LG, Carrasco M, Lopez-Toledano MA, Murillo-Carretero M, Ruiz FA, et al. (2008) Homocysteine inhibits proliferation of neuronal precursors in the mouse adult brain by impairing the basic fibroblast growth factor signaling cascade and reducing extracellular regulated kinase 1/2-dependent cyclin E expression. FASEB J 22: 3823-3835.
16. Schober A, (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318: 215-224.
17. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, et al. (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43: 561-575.
18. Butelman ER, France CP, Woods JH, (1991) The discriminative stimulus effects of MK-801 in pigeons. Behav Pharmacol 2: 79-86.
19. Anderson DW, Neavin T, Smith JA, Schneider JS, (2001) Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 905: 44-53.
20. Kralic JE, Ledergerber DA, Fritschy JM, (2005) Disruption of the neurogenic potential of the dentate gyrus in a mouse model of temporal lobe epilepsy with focal seizures. Eur J Neurosci 22: 1916-1927.
21. Luskin MB, Zigova T, Soteres BJ, Stewart RR, (1997) Neuronal progenitor cells derived from the anterior subventricular zone of the neonatal rat forebrain continue to proliferate in vitro and express a neuronal phenotype. Mol Cell Neurosci 8: 351-366.
22. Wegner F, Kraft R, Busse K, Schaarschmidt G, Hartig W, et al. (2009) Glutamate receptor properties of human mesencephalic neural progenitor cells: NMDA enhances dopaminergic neurogenesis in vitro. J Neurochem 111: 204-216.
23. Charles saller F, Andre Salama I, (1986) D-1 and D-2 Dopamine Receptor Blockade: Interactive Effects in Vitro and in Vivo. Journal of Pharmacology and Experimental Therapeutics 236: 714-720.
24. Kirik D, Rosenblad C, Bjorklund A, (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152: 259-277.
25. West MJ, Slomianka L, Gundersen HJ, (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
26. Sun L, Shipley MT, Lidow MS, (2000) Expression of NR1, NR2A-D, and NR3 subunits of the NMDA receptor in the cerebral cortex and olfactory bulb of adult rat. Synapse 35: 212-221.
27. Cacciapuoti F, (2011) Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis 32: 82-8.
28. Lee ES, Chen H, Charlton CG, Soliman KF, (2005) The Role of Phospholipid Methylation in 1-Methyl-4-Phenyl-Pyridinium Ion (MPP+)-Induced Neurotoxicity in PC12 Cells. Neurotoxicology 26: 945-957.
29. Shepherd KR, Lee ES, Schmued L, Jiao Y, Ali SF, et al. (2006) The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes. Pharmacol Biochem Behav 83: 349-59.
30. Robert K, Pages C, Ledru A, Delabar J, Caboche J, et al. (2005) Regulation of extracellular signal-regulated kinase by homocysteine in hippocampus. Neuroscience 133: 925-935.
31. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, et al. (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20: 6920-6926.
32. Tjiattas L, Ortiz DO, Dhivant S, Mitton K, Rogers E, et al. (2004) Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell 3: 71-76.
33. Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P, et al. (2010) Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment? Curr Med Chem 17: 213-221.
34. Brazel CY, Nunez JL, Yang Z, Levison SW, (2005) Glutamate enhances survival and proliferation of neural progenitors derived from the subventricular zone. Neuroscience 131: 55-65.
35. Nacher J, Varea E, Miguel Blasco-Ibanez J, Gomez-Climent MA, Castillo-Gomez E, et al. (2007) N-methyl-d-aspartate receptor expression during adult neurogenesis in the rat dentate gyrus. Neuroscience 144: 855-864.
36. Haddad JJ, (2005) N-methyl-D-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: a revolving neurochemical axis for therapeutic intervention? Prog Neurobiol 77: 252-282.
37. Jiang Q, Gu Z, Zhang G, Jing G, (2000) N-methyl-D-aspartate receptor activation results in regulation of extracellular signal-regulated kinases by protein kinases and phosphatases in glutamate-induced neuronal apototic-like death. Brain Res 887: 285-292.
38. Hu M, Sun YJ, Zhou QG, Chen L, Hu Y, et al. (2008) Negative regulation of neurogenesis and spatial memory by NR2B-containing NMDA receptors. J Neurochem 106: 1900-1913.
39. Nacher J, Alonso-Llosa G, Rosell DR, McEwen BS, (2003) NMDA receptor antagonist treatment increases the production of new neurons in the aged rat hippocampus. Neurobiol Aging 24: 273-284.
40. Hu M, Sun YJ, Zhou QG, Auberson YP, Chen L, et al. (2009) Reduced spatial learning in mice treated with NVP-AAM077 through down-regulating neurogenesis. Eur J Pharmacol 622: 37-44.
41. Nacher J, McEwen BS, (2006) The role of N-methyl-D-asparate receptors in neurogenesis. Hippocampus 16: 267-270.
42. Mori M, Jefferson JJ, Hummel M, Garbe DS, (2008) CNTF: a putative link between dopamine D2 receptors and neurogenesis. J Neurosci 28: 5867-5869.
43. Winner B, Desplats P, Hagl C, Klucken J, Aigner R, et al. (2009) Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Exp Neurol 219: 543-552.
44. O'Sullivan SS, Johnson M, Williams DR, Revesz T, Holton JL, et al. (2011) The effect of drug treatment on neurogenesis in Parkinson's disease. Mov Disord 26: 45-50.
45. Jenner P, (2002) Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58: S1-8.
46. Deierborg T, Soulet D, Roybon L, Hall V, Brundin P, (2008) Emerging restorative treatments for Parkinson's disease. Prog Neurobiol 85: 407-432.